高剂量的阿莫达菲尼尔在治疗不耐治疗的双极性抑郁症中
Wan Y Kwok1, Victoria Stephens2, Henry A Nasrallah2
1Department of Psychiatry, University of Illinois Chicago, Chicago, Illinois, USA.
概括
高剂量的阿莫达菲尼尔有效地治疗了对其他疗法无反应的患者的严重,耐治疗的双极性抑郁症. 这表明更高的剂量可能对管理这种情况至关重要.
科学领域:
- 神经精神病学是一种神经精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 双极性抑郁症具有显著的发病率和自杀风险.
- 标准抗抑郁药对双极性抑郁症无效,需要替代治疗.
- 现有的双极性抑郁症治疗方法的疗效有限,导致治疗耐药性.
研究的目的:
- 报告一种严重的双极性抑郁症病例,该病例不耐电治疗和IV胺.
- 为了研究高剂量阿莫达菲尼尔在治疗耐药双极性抑郁症中的疗效.
主要方法:
- 一名65岁的女性患者患有严重的双极性抑郁症接受了治疗.
- 治疗需要将阿莫达菲尼尔的剂量逐渐提升至每天1,000毫克.
- 患者的反应和不良反应被监测了五年.
主要成果:
- 患者通过高剂量阿莫达菲尼尔 (1000毫克/天) 实现了缓解,并维持了五年.
- 由于怀疑肌肉病的暂时降低剂量导致抑郁复发.
- 恢复高剂量的阿莫达菲尼尔恢复了缓解和功能能力.
结论:
- 高剂量的阿莫达菲尼尔可以在治疗耐药的双极性抑郁症中有效且耐受良好.
- 在以前的研究中使用的较低剂量可能解释不一致的结果.
- 对阿莫达菲尼尔在双极性抑郁症中最佳剂量的进一步研究是有必要的.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
275
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
275
Mania and Antimanic Drugs: Overview
249
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
249
Bipolar Disorder
108
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
108
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Psychosis: Goals of Pharmacotherapy
170
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
170
Antidepressant Drugs: Overview
589
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
589


